Biosimilars, Documentation and Medication Dispensing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Biosimilars

Documentation

Medication Dispensing

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

JUNE 17, 2025

This research shows the impactful interventions implemented within a medically integrated pharmacy (MIP) model, specifically focusing on how oncology-trained nurses can leverage comprehensive chart reviews and reassessments to identify discrepancies before medication dispensation, ultimately leading to substantial cost avoidance and waste reduction.

Mail-Order Pharmacies

Mail-Order Pharmacies Pharmacy Technician Compounding Pharmacies Inpatient

New Breakthrough Devices Program Guidance: Expanding Opportunities for Medical Product Innovations

FDA Law Blog: Biosimilars

OCTOBER 17, 2023

Background The Breakthrough Devices Program, established under section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), is a voluntary program for certain medical devices and device-led combination products. By Philip Won & Lisa M. Wysa, see here ) and addiction (e.g., reSET-O, see here , here ).

Documentation

Documentation Medication Dispensing Hospitals

Pharmacist Digest

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

New Breakthrough Devices Program Guidance: Expanding Opportunities for Medical Product Innovations

Stay Connected